19960209
 U.K.'s Zeneca Wins In Glaxo's Forced Sale Of Migraine Medicine   The Wall Street Journal,  Feb 9, 1996  The proposed transaction -- expected to be completed by the end of this month -- would fulfill a condition imposed by the U.S. Federal Trade Commission in approving Glaxo's #9.4 billion ($14.45 billion) takeover of Wellcome PLC last year. Wellcome discovered 311C -- but FTC antitrust officials worried that the drug might give Glaxo too dominant a position in migraine medicine. Glaxo already markets one successful migraine drug, Imigran, and has a second follow-up compound at an advanced stage of development.   
